3-D Matrix

Basic Information

Stock Code
7777
Industry
Precision Instruments
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
February 2009
Listing Year
October 2011
Official Website
http://www.3d-matrix.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, North Japan Spinning, Axelmark, Nexel Pharma, Kaiom Bioscience, Kids Well Bio, Medorex, Peptidream, Ribomic, SanBio, Helios, Brightpath Bio, Solasia Pharma, Renascience, QualiPS, Takara Bio, Trace One Product, Japan Tissue Engineering, RISE

Overview

3-D Matrix is a bio-venture established in 2004, an advanced company engaged in the research, development, manufacturing, and sales of medical materials using self-assembling peptide technology.

Current Situation

3-D Matrix has consolidated sales of approximately ¥100 million and continues to post operating deficits, but it is a bio-venture company specializing in the development of medical materials utilizing self-assembling peptide technology. Its main products are medical materials, for which it has acquired an exclusive patent implementation license from MIT, holding technological superiority. With 37 employees, it maintains a highly specialized R&D system despite its small scale. The market focuses on medical biopharmaceuticals and medical materials, differentiating technologically from competitors. Moving forward, it aims to expand its product lineup and pursue overseas expansion while balancing financial improvement with R&D investment. Regarding sustainability, it is gaining attention for reducing the environmental impact of bio-materials and developing sustainable medical technologies. In the long term, it seeks to pioneer new markets in the medical field by expanding applications of self-assembling peptides. It is strengthening competitiveness through proactive technology licensing and partnership strategies.

Trivia

Interesting Facts

  • One of the few Japanese companies licensed with patents from MIT
  • Self-assembling peptides mimic natural protein structures, a cutting-edge technology
  • Boasts high technological prowess with only 37 employees
  • Attracting attention in the medical field since its TSE Growth listing in 2011
  • Much of its R&D is advanced in collaboration between the US and Japan
  • Patent technology applicable to a wide range from drug discovery to medical materials
  • While many competitors focus on drug discovery, the company specializes in material development
  • One of the pioneering bio-ventures based in Chiyoda-ku, Tokyo
  • Achieves product manufacturing meeting international standards despite small organization
  • Self-assembling peptide technology highly evaluated in medical settings for biocompatibility
  • Continues R&D investment despite ongoing consolidated deficits
  • Expected expansion in applications as medical materials going forward
  • Bio-material company trusted by academic research institutions
  • Ongoing technology collaboration with US MIT spin-off subsidiary
  • Rare possession of exclusive patent rights as a medical materials manufacturer

Hidden Connections

  • Serves as a bridge connecting the US and Japan through technology collaboration as an MIT-originated venture
  • Contributes to research material supply for major pharmaceutical companies via patent licenses
  • Self-assembling peptide technology gaining attention as a bridge between regenerative medicine and drug discovery
  • Opportunities for partnerships with domestic and international competitors in medical adhesive field
  • Elite technical team earning high evaluations in Japan's bio-venture community
  • Valuable presence in medical bio sector as TSE Growth-listed company
  • Adopted in specific frameworks in medical materials industry due to R&D achievements
  • Actively participates in joint technical research with overseas bio-ventures

Future Outlook

Growth Drivers

  • Expansion of self-assembling peptide technology applications in medical field
  • Increasing demand for regenerative medicine amid aging society
  • Expansion of needs for minimally invasive surgery and adhesives
  • Global growth trend in medical materials market
  • Active overseas market entry plans
  • Ongoing technological innovation through continued MIT collaboration
  • Increasing adoption and high evaluations from medical institutions
  • Growing demand for environmentally considerate materials
  • Utilization of government support measures for bio-ventures
  • Revenue diversification through licensing business

Strategic Goals

  • Achieve sustainable growth with sales exceeding ¥1 billion
  • Global deployment of self-assembling peptide products
  • Achieve launch of multiple new regenerative medicine products
  • Continuous promotion of profitability and margin improvements
  • Integrate environmental impact reduction and sustainability into corporate value
  • Strengthen technological collaboration through overseas partnerships
  • Enhance R&D organization and thorough talent development
  • Expand market share in medical adhesive sector
  • Actively secure and utilize public support and grants
  • Expand regional deployment and impact of social contribution activities

Business Segments

Medical Materials Business for Medical Institutions

Overview
Manufactures and supplies medical materials using self-assembling peptides to medical institutions.
Competitiveness
Uniqueness from MIT patent technology license
Customers
  • University hospitals
  • General hospitals
  • Clinics
  • Regenerative medicine facilities
  • Research institutions
  • Medical device manufacturers
  • Surgical instrument distributors
Products
  • 3-D Matrix Scaffold
  • BioMatrix Surgical Sealant
  • PeptiMed Gel
  • Medipep Hydrogel
  • HealPep Wound Dressing

Research Materials for Pharmaceutical Companies

Overview
Provides materials for cell culture and regenerative medicine research to pharmaceutical companies.
Competitiveness
Provision of advanced functional peptide materials
Customers
  • Pharmaceutical companies
  • Biotechnology companies
  • Academic research institutions
  • Clinical trial facilities
Products
  • Cell culture scaffold materials
  • Regenerative medicine patches
  • Biogel product lineup

Joint Development with Research Institutions

Overview
Promotes technology partnerships and joint development projects with research institutions.
Competitiveness
Flexible technology support system and MIT collaboration
Customers
  • University labs
  • Public research institutes
  • Medical venture companies
Products
  • Technology transfer
  • Reagents for joint research
  • Support for patent technology implementation

Overseas Expansion and Licensing Business

Overview
Expands licensing business for overseas markets.
Competitiveness
International credibility of MIT-derived technology
Customers
  • Overseas medical device manufacturers
  • International bio companies
  • Medical-related investors
Products
  • Patent technology license provision
  • OEM contract manufacturing

Raw Materials Supply for Biomaterial Research

Overview
Supplies raw materials for medical materials for research purposes.
Competitiveness
Provision of high-purity, high-functionality materials
Customers
  • Materials science institutes
  • Advanced medical researchers
  • Manufacturers
Products
  • Self-assembling peptide raw materials
  • Medical biomaterials

Competitive Advantage

Strengths

  • Proprietary self-assembling peptide technology
  • Exclusive patent implementation rights from MIT
  • Elite team of specialized researchers
  • Specialization in medical biomaterials
  • High technological development capabilities
  • Flexible technology licensing deployment
  • Recognition in advanced medical fields
  • Certain stability in consolidated financial base
  • Network with medical institutions
  • Collaborative relationships with research institutions
  • Potential for overseas expansion
  • Agility unique to focused SMEs
  • Numerous self-assembling peptide application products developed
  • Continuous pursuit of technological innovation
  • Product lineup with high biocompatibility

Competitive Advantages

  • Product superiority from utilizing MIT-derived exclusive patent technology
  • Specialization in niche medical biomaterial market
  • Advanced R&D capabilities and swift decision-making despite small scale
  • Deployment of proprietary materials aimed at reducing patient burden
  • Diverse product lineup tailored to medical site needs
  • Maintenance of high-standard quality control systems
  • Introduction of latest technologies through collaboration with world-class research institutions
  • Development capabilities for hemostasis and adhesion materials based on proprietary materials
  • Potential for market expansion through international licensing agreements
  • Possession of advanced bio-processing technology
  • Strict compliance with regulations regarding product safety
  • Capability to develop new applications based on specialized knowledge
  • Swift and flexible customer response capabilities
  • Ongoing investment stance in R&D
  • High barriers to entry for competitors in specialized areas

Threats

  • Risk of intensified regulations in medical device market
  • Fierce competition with major pharmaceutical companies
  • Financial strain from rising R&D costs
  • Concerns over patent expiration or technological obsolescence
  • Market demand fluctuations and intensifying technological competition
  • Challenges in overseas expansion regarding legal systems and certifications
  • Potential price competition from new entrants
  • Delays in adoption at medical sites or changes in evaluation criteria
  • Sales compression due to shortened product life cycles
  • Risk of fluctuating fundraising environment
  • Changes in medical field environment due to pandemic outbreaks, etc.
  • Risk of quality and safety issues with biomaterials

Innovations

2023: Development of Scalable Self-Assembling Peptide Materials

Overview
Developed new peptide materials to expand the application range of medical materials.
Impact
Diversification of product lineup and strengthened market competitiveness

2022: Launch of Improved Rapid Surgical Adhesive Product

Overview
Commercialized a medical adhesive with improved adhesion quick-drying and safety.
Impact
Contributes to shortening surgery time and reducing patient burden

2024: Initiation of Clinical Trials for Regenerative Medicine Patch Product

Overview
Clinical trials for a bio-patch for skin regeneration have commenced.
Impact
Expectations for entry into new medical product markets

2021: Renegotiation and Expansion of MIT Technology Patents

Overview
Concluded an expanded patent agreement with MIT to broaden the scope of technology use.
Impact
Extension of technology foundation lifespan and strengthened future prospects

Sustainability

  • Promotion of measures to reduce environmental impact of regenerative medical materials
  • Research to improve biodegradability of biomaterials
  • Introduction of environmentally considerate manufacturing processes
  • Proper management and reduction efforts for medical waste
  • Active participation in regional medical support activities
  • Pursuit of developing sustainable bio-materials
  • Energy-efficient factory operations
  • Implementation of environmental education for employees
  • Promotion of product safety and proper use awareness
  • Environmental compliance audits of supply chains
  • Promotion of ethical technology development
  • Promotion of corporate culture respecting diversity